Platelet Microparticles Mediate Glomerular Endothelial Injury in Early Diabetic Nephropathy

J Am Soc Nephrol. 2018 Nov;29(11):2671-2695. doi: 10.1681/ASN.2018040368. Epub 2018 Oct 19.

Abstract

Background: Glomerular endothelium dysfunction, which plays a crucial role in the pathogenesis of early diabetic nephropathy, might be caused by circulating metabolic abnormalities. Platelet microparticles, extracellular vesicles released from activated platelets, have recently emerged as a novel regulator of vascular dysfunction.

Methods: We studied the effects of platelet microparticles on glomerular endothelial injury in early diabetic nephropathy in rats with streptozotocin-induced diabetes and primary rat glomerular endothelial cells. Isolated platelet microparticles were measured by flow cytometry.

Results: Plasma platelet microparticles were significantly increased in diabetic rats, an effect inhibited in aspirin-treated animals. In cultured glomerular endothelial cells, platelet microparticles induced production of reactive oxygen species, decreased nitric oxide levels, inhibited activities of endothelial nitric oxide synthase and SOD, increased permeability of the glomerular endothelium barrier, and reduced thickness of the endothelial surface layer. Conversely, inhibition of platelet microparticles in vivo by aspirin improved glomerular endothelial injury. Further analysis showed that platelet microparticles activated the mammalian target of rapamycin complex 1 (mTORC1) pathway in glomerular endothelial cells; inhibition of the mTORC1 pathway by rapamycin or raptor siRNA significantly protected against microparticle-induced glomerular endothelial injury in vivo and in vitro. Moreover, platelet microparticle-derived chemokine ligand 7 (CXCL7) contributed to glomerular endothelial injury, and antagonizing CXCL7 using CXCL7-neutralizing antibody or blocking CXCL7 receptors with a competitive inhibitor of CXCR1 and CXCR2 dramatically attenuated such injury.

Conclusions: These findings demonstrate a pathogenic role of platelet microparticles in glomerular endothelium dysfunction, and suggest a potential therapeutic target, CXCL7, for treatment of early diabetic nephropathy.

Keywords: CXCL7; Platelet microparticles; diabetic nephropathy; endothelial injury; mTORC1 pathway.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aspirin / pharmacology
  • Blood Platelets / drug effects
  • Blood Platelets / pathology
  • Blood Platelets / physiology*
  • Cell-Derived Microparticles / drug effects
  • Cell-Derived Microparticles / pathology
  • Cell-Derived Microparticles / physiology*
  • Cells, Cultured
  • Chemokines, CXC / physiology
  • Diabetes Mellitus, Experimental / blood*
  • Diabetes Mellitus, Experimental / pathology
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetic Nephropathies / blood*
  • Diabetic Nephropathies / pathology
  • Diabetic Nephropathies / physiopathology
  • Endothelial Cells / pathology
  • Kidney Glomerulus / blood supply
  • Kidney Glomerulus / drug effects
  • Kidney Glomerulus / pathology*
  • Male
  • Mechanistic Target of Rapamycin Complex 1 / antagonists & inhibitors
  • Mechanistic Target of Rapamycin Complex 1 / physiology
  • Platelet Activation
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction

Substances

  • Chemokines, CXC
  • Ppbp protein, rat
  • Mechanistic Target of Rapamycin Complex 1
  • Aspirin